Gena Wang
Stock Analyst at Barclays
(3.26)
# 1,047
Out of 5,055 analysts
237
Total ratings
45.1%
Success rate
2.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $94 → $90 | $30.29 | +197.13% | 7 | Nov 13, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $10.79 | +205.84% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $24.77 | +0.93% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $8.70 | +60.92% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.44 | +124.87% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $75.30 | -9.69% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $18.81 | +6.33% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $437.15 | -5.30% | 18 | Nov 4, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $10 → $9 | $4.24 | +112.26% | 8 | Nov 4, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Equal-Weight | $11 → $9 | $7.08 | +27.12% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $449.16 | +17.33% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $71.55 | +32.77% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $54.73 | +46.17% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.90 | +105.13% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $82 | $66.44 | +23.42% | 4 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $19.51 | -12.87% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $11.51 | +221.46% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $70.80 | -12.43% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $52.53 | +6.61% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $21.72 | -3.31% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.63 | +450.62% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.60 | +15.38% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $33.08 | +144.86% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $18.52 | -51.40% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $7.27 | +243.88% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.18 | +120.05% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $4.89 | +84.05% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $4.45 | +6,079.78% | 1 | Jan 6, 2017 |
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $94 → $90
Current: $30.29
Upside: +197.13%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $10.79
Upside: +205.84%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $24.77
Upside: +0.93%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $8.70
Upside: +60.92%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.44
Upside: +124.87%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $75.30
Upside: -9.69%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $18.81
Upside: +6.33%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $437.15
Upside: -5.30%
Solid Biosciences
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $4.24
Upside: +112.26%
BioCryst Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $7.08
Upside: +27.12%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $449.16
Upside: +17.33%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $71.55
Upside: +32.77%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $54.73
Upside: +46.17%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.90
Upside: +105.13%
Oct 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $66.44
Upside: +23.42%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $19.51
Upside: -12.87%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $11.51
Upside: +221.46%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $70.80
Upside: -12.43%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $52.53
Upside: +6.61%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $21.72
Upside: -3.31%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.63
Upside: +450.62%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.60
Upside: +15.38%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $33.08
Upside: +144.86%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $18.52
Upside: -51.40%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $7.27
Upside: +243.88%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.18
Upside: +120.05%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $4.89
Upside: +84.05%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $4.45
Upside: +6,079.78%